体外生命维持电路提取头孢吡肟。

Q2 Health Professions
Danielle J Green, Kevin M Watt, Douglas N Fish, Autumn McKnite, Walter Kelley, Adam R Bensimhon
{"title":"体外生命维持电路提取头孢吡肟。","authors":"Danielle J Green,&nbsp;Kevin M Watt,&nbsp;Douglas N Fish,&nbsp;Autumn McKnite,&nbsp;Walter Kelley,&nbsp;Adam R Bensimhon","doi":"10.1182/ject-212-222","DOIUrl":null,"url":null,"abstract":"<p><p>Extracorporeal life support (ECLS) devices are lifesaving for critically ill patients with multi-organ dysfunction. Despite this, patients supported with ECLS are at high risk for ECLS-related complications, including nosocomial infections, and mortality rates are high in this patient population. The high mortality rates are suspected to be, in part, a result of significantly altered drug disposition by the ECLS circuit, resulting in suboptimal antimicrobial dosing. Cefepime is commonly used in critically ill patients with serious infections. Cefepime dosing is not routinely guided by therapeutic drug monitoring and treatment success is dependent upon the percentage of time of the dosing interval that the drug concentration remains above the minimum inhibitory concentration of the organism. This <i>ex vivo</i> study measured the extraction of cefepime by continuous renal replacement therapy (CRRT) and extracorporeal membrane oxygenation (ECMO) circuits. Cefepime was studied in four closed-loop CRRT circuit configurations and a single closed-loop ECMO circuit configuration. Circuits were primed with a physiologic human blood-plasma mixture and the drug was dosed to achieve therapeutic concentrations. Serial blood samples were collected over time and concentrations were quantified using validated assays. In <i>ex vivo</i> CRRT experiments, cefepime was rapidly cleared by dialysis, hemofiltration, and hemodiafiltration, with greater than 96% cefepime eliminated from the circuit by 2 hours. In the ECMO circuits, the mean recovery of cefepime was similar in both circuit and standard control. Mean (standard deviation) recovery of cefepime in the ECMO circuits (<i>n</i> = 6) was 39.2% (8.0) at 24 hours. Mean recovery in the standard control (<i>n</i> = 3) at 24 hours was 52.2% (1.5). Cefepime is rapidly cleared by dialysis, hemofiltration, and hemodiafiltration in the CRRT circuit but minimally adsorbed by either the CRRT or ECMO circuits. Dosing adjustments are needed for patients supported with CRRT.</p>","PeriodicalId":39644,"journal":{"name":"Journal of Extra-Corporeal Technology","volume":"54 3","pages":"212-222"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891479/pdf/ject-212-222.pdf","citationCount":"1","resultStr":"{\"title\":\"Cefepime Extraction by Extracorporeal Life Support Circuits.\",\"authors\":\"Danielle J Green,&nbsp;Kevin M Watt,&nbsp;Douglas N Fish,&nbsp;Autumn McKnite,&nbsp;Walter Kelley,&nbsp;Adam R Bensimhon\",\"doi\":\"10.1182/ject-212-222\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Extracorporeal life support (ECLS) devices are lifesaving for critically ill patients with multi-organ dysfunction. Despite this, patients supported with ECLS are at high risk for ECLS-related complications, including nosocomial infections, and mortality rates are high in this patient population. The high mortality rates are suspected to be, in part, a result of significantly altered drug disposition by the ECLS circuit, resulting in suboptimal antimicrobial dosing. Cefepime is commonly used in critically ill patients with serious infections. Cefepime dosing is not routinely guided by therapeutic drug monitoring and treatment success is dependent upon the percentage of time of the dosing interval that the drug concentration remains above the minimum inhibitory concentration of the organism. This <i>ex vivo</i> study measured the extraction of cefepime by continuous renal replacement therapy (CRRT) and extracorporeal membrane oxygenation (ECMO) circuits. Cefepime was studied in four closed-loop CRRT circuit configurations and a single closed-loop ECMO circuit configuration. Circuits were primed with a physiologic human blood-plasma mixture and the drug was dosed to achieve therapeutic concentrations. Serial blood samples were collected over time and concentrations were quantified using validated assays. In <i>ex vivo</i> CRRT experiments, cefepime was rapidly cleared by dialysis, hemofiltration, and hemodiafiltration, with greater than 96% cefepime eliminated from the circuit by 2 hours. In the ECMO circuits, the mean recovery of cefepime was similar in both circuit and standard control. Mean (standard deviation) recovery of cefepime in the ECMO circuits (<i>n</i> = 6) was 39.2% (8.0) at 24 hours. Mean recovery in the standard control (<i>n</i> = 3) at 24 hours was 52.2% (1.5). Cefepime is rapidly cleared by dialysis, hemofiltration, and hemodiafiltration in the CRRT circuit but minimally adsorbed by either the CRRT or ECMO circuits. Dosing adjustments are needed for patients supported with CRRT.</p>\",\"PeriodicalId\":39644,\"journal\":{\"name\":\"Journal of Extra-Corporeal Technology\",\"volume\":\"54 3\",\"pages\":\"212-222\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891479/pdf/ject-212-222.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Extra-Corporeal Technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1182/ject-212-222\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Health Professions\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Extra-Corporeal Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1182/ject-212-222","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Health Professions","Score":null,"Total":0}
引用次数: 1

摘要

体外生命支持(ECLS)装置是挽救多器官功能障碍危重患者生命的重要手段。尽管如此,接受ECLS治疗的患者发生ECLS相关并发症(包括院内感染)的风险很高,这类患者的死亡率也很高。高死亡率被怀疑部分是由于ECLS电路显著改变了药物配置,导致抗菌药物剂量不理想。头孢吡肟常用于严重感染的危重患者。头孢吡肟的给药不是由治疗药物监测常规指导,治疗成功取决于给药间隔时间的百分比,药物浓度保持在生物体的最低抑制浓度以上。这项体外研究测量了连续肾替代治疗(CRRT)和体外膜氧合(ECMO)回路对头孢吡肟的提取。研究了头孢吡肟在四种CRRT闭环电路配置和单闭环ECMO电路配置中的应用。电路用生理性的人血浆混合物启动,并给药以达到治疗浓度。随着时间的推移,收集了一系列血液样本,并使用有效的测定法对浓度进行了量化。在体外CRRT实验中,通过透析、血液滤过和血液滤过,头孢吡肟被迅速清除,2小时内头孢吡肟从循环中清除的比例超过96%。在ECMO回路中,头孢吡肟在回路和标准对照中的平均回收率相似。ECMO回路(n = 6) 24小时时头孢吡肟的平均(标准差)回收率为39.2%(8.0)。标准对照(n = 3) 24小时平均回收率为52.2%(1.5)。CRRT回路中的透析、血液滤过和血液滤过可迅速清除头孢吡肟,但CRRT或ECMO回路对头孢吡肟的吸附极小。接受CRRT治疗的患者需要调整剂量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Cefepime Extraction by Extracorporeal Life Support Circuits.

Extracorporeal life support (ECLS) devices are lifesaving for critically ill patients with multi-organ dysfunction. Despite this, patients supported with ECLS are at high risk for ECLS-related complications, including nosocomial infections, and mortality rates are high in this patient population. The high mortality rates are suspected to be, in part, a result of significantly altered drug disposition by the ECLS circuit, resulting in suboptimal antimicrobial dosing. Cefepime is commonly used in critically ill patients with serious infections. Cefepime dosing is not routinely guided by therapeutic drug monitoring and treatment success is dependent upon the percentage of time of the dosing interval that the drug concentration remains above the minimum inhibitory concentration of the organism. This ex vivo study measured the extraction of cefepime by continuous renal replacement therapy (CRRT) and extracorporeal membrane oxygenation (ECMO) circuits. Cefepime was studied in four closed-loop CRRT circuit configurations and a single closed-loop ECMO circuit configuration. Circuits were primed with a physiologic human blood-plasma mixture and the drug was dosed to achieve therapeutic concentrations. Serial blood samples were collected over time and concentrations were quantified using validated assays. In ex vivo CRRT experiments, cefepime was rapidly cleared by dialysis, hemofiltration, and hemodiafiltration, with greater than 96% cefepime eliminated from the circuit by 2 hours. In the ECMO circuits, the mean recovery of cefepime was similar in both circuit and standard control. Mean (standard deviation) recovery of cefepime in the ECMO circuits (n = 6) was 39.2% (8.0) at 24 hours. Mean recovery in the standard control (n = 3) at 24 hours was 52.2% (1.5). Cefepime is rapidly cleared by dialysis, hemofiltration, and hemodiafiltration in the CRRT circuit but minimally adsorbed by either the CRRT or ECMO circuits. Dosing adjustments are needed for patients supported with CRRT.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Extra-Corporeal Technology
Journal of Extra-Corporeal Technology Medicine-Medicine (all)
CiteScore
1.90
自引率
0.00%
发文量
12
期刊介绍: The Journal of Extracorporeal Technology is dedicated to the study and practice of Basic Science and Clinical issues related to extracorporeal circulation. Areas emphasized in the Journal include: •Cardiopulmonary Bypass •Cardiac Surgery •Cardiovascular Anesthesia •Hematology •Blood Management •Physiology •Fluid Dynamics •Laboratory Science •Coagulation and Hematology •Transfusion •Business Practices •Pediatric Perfusion •Total Quality Management • Evidence-Based Practices
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信